2022
Trends in characteristics of neurologists who provide stroke consultations in the USA, 2008–2021
Nakamoto C, Wilcock A, Schwamm L, Majersik J, Zachrison K, Mehrotra A. Trends in characteristics of neurologists who provide stroke consultations in the USA, 2008–2021. Stroke And Vascular Neurology 2022, 8: 86-88. PMID: 35902139, PMCID: PMC9985800, DOI: 10.1136/svn-2022-001662.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeTransient ischemic attackVascular neurologistsPatient's homeAIS/transient ischemic attackHigh-volume providersNeurologist consultationTIA episodesIschemic attackIschemic strokeStroke consultationsNeurologistsService MedicarePhysician practicesStudy periodConsultsPatientsEpisodesConsultationHomeHospitalStrokeProportion
2012
Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke
Messé S, Fonarow G, Smith E, Kaltenbach L, Olson D, Kasner S, Schwamm L. Use of Tissue-Type Plasminogen Activator Before and After Publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke. Circulation Cardiovascular Quality And Outcomes 2012, 5: 321-326. PMID: 22550132, DOI: 10.1161/circoutcomes.111.964064.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overEuropeFemaleFibrinolytic AgentsGuideline AdherenceHumansInfusions, IntravenousLinear ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioOutcome and Process Assessment, Health CarePractice Guidelines as TopicStrokeThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorTreatment OutcomeUnited StatesConceptsAcute ischemic strokeEuropean Cooperative Acute Stroke Study (ECASS) IIIECASS IIITreatment of patientsUse of tPAEligible patientsHours of AISProportion of patientsStudy IIITissue-type plasminogen activatorGuidelines-StrokeIschemic strokeMedian doorNeedle timePatientsClinical practiceTreatment ratesPlasminogen activatorSignificant increaseHoursLater time windowAdverse affectsTPATreatmentProportion